ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin in the Phase 3 ATLANTIS Trial

23 views
June 14, 2022
Comments 0
Login to view comments. Click here to Login